On Wednesday, a three‑judge panel of the New Orleans‑based 5th U.S. Circuit Court of Appeals will hear arguments on whether federal prescribing rules for mifepristone – the drug used in the majority of medication abortions – should be tightened. The case, brought by Louisiana Attorney General Liz Murrill and plaintiff Rosalie Markezich, reflects a broader push by anti‑abortion activists, many of whom are staunch supporters of President Trump, to close legal loopholes that keep abortion pills accessible in states with bans.
Background and legal context
Since the Supreme Court’s 2022 Dobbs decision overturned Roe v. Wade, more than three‑quarters of U.S. abortions are performed with a two‑drug regimen of mifepristone and misoprostol. The FDA relaxed its prescribing rules in 2023, allowing telehealth prescriptions and mail delivery, a change that anti‑abortion groups argue defeats state bans.
The 5th Circuit case is one of three similar lawsuits moving through the courts. Earlier panels on the same circuit and two district courts have already found the current FDA rules too permissive. The Supreme Court rejected a 2024 challenge to roll back access, not on the merits but because the plaintiffs lacked legal standing.
Trump administration’s stance
While the administration has largely stayed silent in the courtroom battles, President Trump’s anti‑abortion base remains frustrated that a legal workaround persists. Trump’s latest nominee to lead the FDA, Dr. Heidi Overton – formerly deputy director of the White House Domestic Policy Council – has publicly criticized the agency for loosening mifepristone rules, signaling potential regulatory tightening.
In addition, Republican attorneys general from Florida and Texas have filed a separate lawsuit against the FDA, and the top legal officers of Idaho, Kansas and Missouri have joined another challenge, underscoring a coordinated effort among GOP states to defend the Dobbs intent.
What’s at stake
If the appeals court sides with the plaintiffs, the FDA could be forced to reinstate an in‑person requirement for mifepristone prescriptions, effectively limiting access for patients in states where abortion is otherwise illegal. Advocates warn that such a move would push providers to rely solely on misoprostol, a drug that, while effective on its own, has a lower success rate than the combined regimen.
Pro‑life advocates argue that restoring stricter rules would honor the promise of Dobbs – that states should decide how to regulate abortion. “This case will have a huge impact,” said Gabriella McIntyre, legal counsel for Alliance Defending Freedom, which represents the plaintiffs.
Public opinion and broader implications
Polling cited in the source indicates that a majority of voters still favor legal abortion access, even as anti‑abortion groups intensify legal challenges. The administration’s quiet approach may reflect a strategic decision to let the courts shape policy while the FDA continues its safety review of mifepristone.
One judge has ordered the FDA to provide a status update by Oct. 7, less than a month before the midterm elections, where control of Congress will be contested. The timing suggests that the issue could become a flashpoint in the upcoming political battles.
Potential next steps
Even if the 5th Circuit limits mifepristone distribution, providers say they could shift to prescribing misoprostol alone, preserving some level of access. However, the combined regimen remains the most effective, completing medical abortions in 97.4% of cases according to FDA labeling.
State lawmakers in Mississippi and Texas have already enacted civil and criminal penalties for prescribing abortion pills, further illustrating the growing legal landscape surrounding medication abortions.
As the case proceeds, the Trump administration’s influence on the FDA and the broader regulatory environment will be closely watched by both pro‑life advocates and those defending telehealth access to reproductive health care.
Original reporting: KTBS 3 (Shreveport) — read the source article.
